Combination therapy for advanced lung cancer after first treatment
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a combination of three drugs (nab-paclitaxel, lenvatinib, and pembrolizumab) for people with advanced non-small cell lung cancer whose cancer grew after first-line treatment with immunotherapy and chemo. The goal is to see if this combination can help control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a type of lung cancer called non-small cell lung cancer that has spread.
- You have already received a combination of immunotherapy (PD-1/PD-L1) plus chemotherapy as your first treatment.
- Your cancer grew while on that first treatment.
- Your cancer does not have specific gene changes (EGFR, ALK, ROS1) that would be treated differently.
- You are generally well (able to care for yourself) and have not had certain other cancer treatments or health problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of three medicines (Golidocitinib, Tislelizumab, and chemotherapy) as the first treatment for advanced non-small cell lung cancer (NSCLC). It is designed for people whose tumors have at least 1% PD-L1 and who have not had any previous treatment for advanced disease.
This trial is comparing a new combination of two immunotherapy drugs (nivolumab and relatlimab) plus chemotherapy against the standard immunotherapy (pembrolizumab) plus chemotherapy for people with advanced non-squamous non-small cell lung cancer that has a certain protein (PD-L1) on at least 1% of its cells. The goal is to see if the new combination works better.
This trial tests a three-drug combination (ipilimumab, nivolumab, and nogapendekin alfa inbakicept) as a first treatment for people with stage IV or recurrent non-small cell lung cancer. The goal is to see if this approach can help your immune system fight the cancer more effectively.
This trial tests a new combination of two investigational drugs, BNT324 and BNT327, for people with advanced lung cancer that cannot be removed by surgery. It aims to see if the combination is safe and effective for different types of lung cancer, including non-small cell and small cell lung cancer.
This trial compares a new combination of drugs (one that targets cancer cells and another that boosts the immune system) against a standard chemotherapy plus immune therapy combination. The goal is to see if the new approach works better as a first treatment for advanced squamous lung cancer.
This trial tests a new study drug called PF-08634404 combined with standard chemotherapy for people with advanced lung cancer that has not been treated before. It aims to see if this combination works better than chemotherapy alone.
Hear when a new Advanced Non-squamous Non-small-cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.